280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
Election of Directors at Alumis Inc. Annual Meeting - James Tananbaum Elected
Investor Presentation
Annual Report to Security Holders
Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
Reports Year End 2025 Financial Results and Highlights
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 425
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership